Literature DB >> 14705835

Suspected pediatric ingestions: effectiveness of immunoassay screens vs. gas chromatography/mass spectroscopy in the detection of drugs and chemicals.

Patrick B Kyle1, J Lee Spencer, Christine M Purser, Kirk C Eddleman, Arthur S Hume.   

Abstract

Rapid and accurate analytical testing can be of great value when determining treatment for pediatric patients suspected of ingesting an unknown chemical. Though often overlooked, gas chromatography/mass spectroscopy (GC/MS) can be a valuable resource in emergency toxicology testing. In a recent 24-month period (July 1999-June 2001), the Analytical Toxicology Laboratory at the University of Mississippi Medical Center, Jackson, MS, compared the results of GC/MS analysis to results obtained by immunoassay testing. The laboratory tested 139 urine samples referred for STAT toxicology testing from the hospital's Pediatric Emergency Department. All samples were tested in parallel using an immunoassay technique (EMIT) and GC/MS. With analysis by immunoassay, 17.3% of the samples were positive for a drug of abuse. The number of positive drug classes ranged from 0 to 2 per sample (mean 0.17 +/- 0.43) using immunoassay. With analysis by GC/MS, drugs were detected in 88.5% of the samples. The number of drugs detected ranged from 0 to 11 per sample (mean 2.2 +/- 1.8) with GC/MS. A total of 64 different pharmaceuticals were identified by GC/MS. This study shows that analysis by GC/MS offers the clinician a more comprehensive view into the exposure of the pediatric patient presenting with an unknown chemical ingestion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14705835     DOI: 10.1081/clt-120026511

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  1 in total

1.  Selective determination of dimenhydrinate in presence of six of its related substances and potential impurities using a direct GC/MS method.

Authors:  Tarek S Belal; Karim M Abdel-Hay; C Randall Clark
Journal:  J Adv Res       Date:  2015-02-07       Impact factor: 10.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.